Webinars & Videos

An efficient method was developed to purge the heavy metal and control the residue at low level in final G-Quadruplexes oligonucleotide. 

In this talk, we will demonstrate how our unique integrated capability in both peptide and oligonucleotide has enabled our clients to quickly advance important PPMO drugs into clinical studies.

* Explore synthesis strategies and analytical methodologies
* Compare the advantages and disadvantages of different formulation strategies
* Review the latest CMC strategies and regulatory framework

* Examine the synthesis and modification of oligonucleotides
* Explore methods for determining pharmacokinetic parameters
* Hear about state of the art discovery strategies

WuXi STA’s William Fang, Vice President and Head of New Modalities Oligo & Peptide, discussed trends in oligonucleotide drug development in this virtual panel discussion published in the magazine Chemistry Today.

WuXi STA New Modality CRDMO Business Introduction